Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
- Published In:
- Diabetes, obesity & metabolism, 26(11), 5312-5324 (2024)
- Authors:
- Ji, Linong(8), Lu, Yibing(3), Shen, Zewei, Hu, Ping, Liu, Wenyan, Zhang, Qiu, Shi, Bimin
- Database ID:
- RPEP-08476
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08476APA
Ji, Linong; Lu, Yibing; Shen, Zewei; Hu, Ping; Liu, Wenyan; Zhang, Qiu; Shi, Bimin. (2024). Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.. Diabetes, obesity & metabolism, 26(11), 5312-5324. https://doi.org/10.1111/dom.15888
MLA
Ji, Linong, et al. "Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.." Diabetes, 2024. https://doi.org/10.1111/dom.15888
RethinkPeptides
RethinkPeptides Research Database. "Impact of baseline characteristics on the efficacy of once-w..." RPEP-08476. Retrieved from https://rethinkpeptides.com/research/ji-2024-impact-of-baseline-characteristics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.